I’m taking the liberty of cross posting this post I wrote from the UK CLL Facebook group.
I’m trying to get my own head round what are the best first line treatments for CLL. Not least because I know that I’m obviously quite likely to need treatment at some point.
I believe in the power of many brains being better than one, so I am very keen to hear if I’ve missed something or got something wrong below. And to hear others personal views or perspectives.
I had a quick look at NICE pathways (see pathways.nice.org.uk/pathwa... ).
The take home message I get is that NICE has recommended FCR as the sole first line option for patients without 17p/TP53. Bendamustine (B) is allowable only if FCR is not suitable.
None of the newer small molecules are allowed as first line options in England by NICE unless you have 17p/TP53.
I’d be interested to know if anyone has managed to get NHS or private insurance to fund small molecules rather than FCR in any other circumstances as their first treatment.
This all makes us very different than the USA. And I think we in the UK need to be very aware that these decisions are largely financial. Some CLL experts in the USA are moving completely away from offering FCR first line. Now, having said that I’m not 100% sure if the evidence fully supports that course of action either quite yet, but I may be wrong on that.
I’ve not read as much as I would like. And the NICE evidence reviews linked there are worth us reading if we want to really understand the data.
But from what I have read I’m getting the idea that the following is probably generally true. Would be interested in others comments on this as I may have missed something.
FCR
Pros: time limited treatment, can introduce long-term remissions that can look almost like cures.
Cons: it’s chemotherapy and so you are essentially taking a poison and trying to kill cancer cells but not too many of your own. It has many side effects including the possibility of causing the CLL cells to mutate / evolve and become more aggressive. Hence taken too early and when it’s not yet needed it may even hasten death. It can also because it is chemo also trigger other secondary cancers years later. It also doesn’t have as good a chance to work if you have 17p/TP53 or possibly also if you are unmutated.
Small molecules
Pros: great responses seen even in those who failed chemotherapy especially with both ventoclax (V) and ibrutinib (I) given in combination. It seems that very good responses that look like a cure are also potentially possible. Perhaps if given earlier on when the CLL burden is lower it may even be possible to induce a genuine cure by literally wiping out all the cancer cells.
Cons: long term and possibly life long treatment may be required. Some very positive eight year data is the longest we have at the moment for any of these medicines as far as I’m aware. It’s possible (maybe even likely?) that evolution of CLL to more aggressive and resistant will also happen at some point with these medicines too. One argument against their early use might be, if one of these drugs or a combination of them will buy you a five to ten year remission and you want to live for twenty years or more you might be better to either continue in watch and wait for as long as possible (but not too long...) or be treated with another bullet rather than reaching first for the golden bullet.
As far as I understand it, with the possible exception of very aggressive disease we aren’t usually offered bone marrow / stem cell transplants as first line treatments.
In summary we know that FCR is a very good treatment for some. We know that the newer drugs are also good for many, and indeed are clearly better if you have 17p/TP53, might be better if you are unmutated, and we are not really sure whether FCR first then small molecules or small molecules first then FCR / other chemo / transplants may be better.
When there is genuine clinical uncertainty because of the lack evidence base for a choice between treatment combinations a clinical trial is the best option. Best not just for the patient because there is actually no way of knowing which treatment combination is best for them so letting a computer choose is just as good as a human, but also for the rest of us since it is clinical trials of the past that led doctors to conclude FCR was the best cocktail of chemo drugs available to us. There’s an argument for saying we owe it to those who went before us and put their lives on the line to prove FCR works to similarly help future generations know in which circumstances it should now be replaced.
Since we are now in a transition time where we have one well known clear favorite chemo combination and several newer small molecules, more clinical data is desperately and urgently needed to show us what is the best first treatment combination for future patients.
Given all that, my conclusion is that when I do need treatment I definitely need to consider being part of the FLAIR trial.
Why? Well I’m not personally that keen on taking chemo (is anyone?) but we don’t really know if chemo or the newer drugs are better for those without 17p/TP53.
The options in FLAIR are FCR, IR, I, IV. Any of those could turn out to be the best combination.
Also if you are taking one of those combinations in the trial and it doesn’t work, you can obviously move to a different combination outside the trial at a later stage.
So, fellow UK CLL warriors it would seem to me (and again, have I missed anything?) that if you are offered treatment for CLL you should definitely ensure you know your genetic status and particularly if you have 17p/TP53. And if you don’t, then it may be a good idea to at least consider asking to be referred to a Centre offering FLAIR for a review and discussion of that trial before accepting other treatment.
See lymphomas.org.uk/lymphoma-t... for more information where you can even refer yourself. If you do want to be referred you can ask your existing haematologist or your GP to refer you to one of these sites for a second opinion and discussion of the trial without committing yourself to definitely take part.